[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 3 of about 3
1. Farré X, Guillén-Gómez E, Sánchez L, Hardisson D, Plaza Y, Lloberas J, Casado FJ, Palacios J, Pastor-Anglada M: Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer; 2004 Dec 20;112(6):959-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors.
  • These 2 antisera, along with a previously characterized antibody that specifically recognizes the high-affinity Na-dependent concentrative NT, hCNT1, have been used to analyze, using a tissue array approach, NT expression in gynecologic cancers (90 ovarian, 80 endometrial and 118 uterine cervix carcinomas).
  • Human CNT1 was not detected in 33% and 39% of the ovarian and uterine cervix carcinomas, respectively, whereas hENT1 and hENT2 expression was significantly retained in a high percentage of tumors (91% and 96% for hENT1, 84% and 98% for hENT2, in ovarian and cervix carcinomas, respectively).
  • In ovarian cancer, the loss of all 3 NT proteins was a more common event in the clear cell histologic subtype than in the serous, mucinous and endometrioid histotypes.
  • In uterine cervix tumors, the loss of expression of hCNT1 was significantly associated with the adenocarcinoma subtype.
  • Moreover, NT expression is related to the type of gynecologic tumor and its specific subtype, hCNT1 protein loss being highly correlated with poor prognosis histotypes.
  • Since hCNT1, hENT1 and hENT2 recognize fluoropyrimidines as substrates, but with different affinities, this study anticipates high variability in drug uptake efficiency in solid tumors.
  • [MeSH-major] Carcinoma / chemistry. Equilibrative Nucleoside Transporter 1 / analysis. Equilibrative-Nucleoside Transporter 2 / analysis. Genital Neoplasms, Female / chemistry. Membrane Transport Proteins / analysis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma, Clear Cell / chemistry. Adenocarcinoma, Mucinous / chemistry. Antibodies, Neoplasm / analysis. Carcinoma, Endometrioid / chemistry. Carcinoma, Squamous Cell / chemistry. Cystadenocarcinoma, Serous / chemistry. Endometrial Neoplasms / chemistry. Female. Gene Expression Regulation, Neoplastic. Humans. Immune Sera. Ovarian Neoplasms / chemistry. Uterine Cervical Neoplasms / chemistry

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15386342.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Equilibrative Nucleoside Transporter 1; 0 / Equilibrative-Nucleoside Transporter 2; 0 / Immune Sera; 0 / Membrane Transport Proteins; 0 / cif nucleoside transporter
  •  go-up   go-down


2. Abadi MA, Barakat RR, Saigo PE: Effects of tamoxifen on cervicovaginal smears from patients with breast cancer. Acta Cytol; 2000 Mar-Apr;44(2):141-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the effect of tamoxifen on cervicovaginal epithelium and determine the value of cervicovaginal smears in identifying patients at risk for endometrial carcinoma.
  • STUDY DESIGN: A group of 48 women with prior breast cancer were divided into three groups: A, tamoxifen-treated patients who developed endometrial carcinoma (n = 20); B, patients with endometrial cancer not treated with tamoxifen (n = 22); and C, tamoxifen-treated patients with no endometrial carcinoma (n = 16).
  • A total of 114 cervicovaginal smears from these patients were evaluated for maturation index, histiocytes, benign and malignant endometrial cells, reactive cellular changes and microorganisms.
  • Histiocytes were also significantly increased in the two groups that subsequently developed endometrial carcinoma (A and B) as compared to the group that did not (group C) (P = .02).
  • However, the presence of endometrial cells in the smears indicated a higher risk of endometrial adenocarcinoma.
  • [MeSH-major] Breast Neoplasms / drug therapy. Carcinoma, Endometrioid / chemically induced. Cervix Uteri / drug effects. Endometrial Neoplasms / chemically induced. Estrogen Antagonists / adverse effects. Tamoxifen / adverse effects
  • [MeSH-minor] Aged. Antineoplastic Agents, Hormonal / adverse effects. Epithelial Cells / drug effects. Epithelial Cells / pathology. Female. Humans. Middle Aged. Mitotic Index / drug effects. Vaginal Smears


Advertisement
3. Ajit D, Gavas S, Jagtap S, Chinoy RF: Cytodiagnostic problems in cervicovaginal smears from symptomatic breast cancer patients on tamoxifen therapy. Acta Cytol; 2009 Jul-Aug;53(4):383-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytodiagnostic problems in cervicovaginal smears from symptomatic breast cancer patients on tamoxifen therapy.
  • Of 4 patients with a cytodiagnosis of atypical glandular changes, 2 had negative histology; 1 each had a uterine leiomyoma and endometrial hyperplasia.
  • Of the 6 cases reported as adenocarcinoma, 3 were histologically confirmed, and the others were false positives.
  • Conversely, 1 false negative case histologically was an endometrioid carcinoma.
  • To avoid diagnostic errors, cervicovaginal smears should be repeated after discontinuing tamoxifen treatment.
  • [MeSH-major] Cervix Uteri / pathology. Tamoxifen / adverse effects. Uterine Cervical Neoplasms / pathology. Vagina / pathology. Vaginal Neoplasms / pathology. Vaginal Smears
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Diagnosis, Differential. False Positive Reactions. Female. Humans. Middle Aged






Advertisement